Akademska digitalna zbirka SLovenije - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov konzorcija SI. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 83
1.
  • 89Zr-DFO-Durvalumab PET/CT ... 89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
    Verhoeff, Sarah R; van de Donk, Pim P; Aarntzen, Erik HJG ... The Journal of nuclear medicine (1978), 10/2022, Letnik: 63, Številka: 10
    Journal Article
    Recenzirano
    Odprti dostop

    In this PD-L1 ImagiNg to prediCt durvalumab treatment response in SCCHN (PINCH) study, we performed 89Zr-DFO-durvalumab (anti–PD-L1 programmed death ligand 1) PET/CT in patients with recurrent or ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK
2.
  • The Influence of Adjuvant S... The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype
    Kramer, Iris; Schaapveld, Michael; Oldenburg, Hester S A ... JNCI : Journal of the National Cancer Institute, 07/2019, Letnik: 111, Številka: 7
    Journal Article
    Recenzirano
    Odprti dostop

    Abstract Background An increasing number of breast cancer (BC) survivors are at risk of developing contralateral breast cancer (CBC). We aimed to investigate the influence of various adjuvant ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
3.
  • A phase 1b study evaluating... A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging
    Jager, Agnes; de Vries, Elisabeth G. E.; der Houven van Oordt, C. Willemien Menke-van ... Breast cancer research, 09/2020, Letnik: 22, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    Abstract Background Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK, VSZLJ

PDF
4.
  • PET‐CT Imaging of Polymeric... PET‐CT Imaging of Polymeric Nanoparticle Tumor Accumulation in Patients
    Miedema, Iris H. C.; Zwezerijnen, Gerben J. C.; Huisman, Marc C. ... Advanced materials, 05/2022, Letnik: 34, Številka: 21
    Journal Article
    Recenzirano
    Odprti dostop

    Several FDA/EMA‐approved nanomedicines have demonstrated improved pharmacokinetics and toxicity profiles compared to their conventional chemotherapeutic counterparts. The next step to increase ...
Celotno besedilo
Dostopno za: BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SAZU, SBCE, SBMB, UL, UM, UPUK
5.
  • Hepatosplenic Candidiasis W... Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
    van Prehn, Joffrey; Menke‐van der Houven van Oordt, C. Willemien; de Rooij, Madelon L. ... The oncologist (Dayton, Ohio), August 2017, Letnik: 22, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    Introduction Patients with a history of chemotherapy or stem cell transplantation (SCT) and prolonged neutropenia are at risk for hepatic and/or splenic seeding of Candida. In our experience, ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
6.
  • Systemic Therapy for Patien... Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
    Werter, Inge M; Remmelzwaal, Sharon; Burchell, George L ... Cancers, 11/2022, Letnik: 14, Številka: 22
    Journal Article
    Recenzirano
    Odprti dostop

    Patients with HER2-positive (HER2+) metastatic breast cancer (mBC) develop brain metastases (BM) in up to 30% of cases. Treatment of patients with BM can consist of local treatment (surgery and/or ...
Celotno besedilo
Dostopno za: IZUM, KILJ, NUK, PILJ, PNG, SAZU, UL, UM, UPUK
7.
  • Clinical Validity of 16α-[ ... Clinical Validity of 16α-[ 18 F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer
    van Geel, Jasper J L; Boers, Jorianne; Elias, Sjoerd G ... Journal of clinical oncology, 11/2022, Letnik: 40, Številka: 31
    Journal Article
    Recenzirano
    Odprti dostop

    Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α- Ffluoro-17β-estradiol positron emission tomography ( FFES-PET) ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK
8.
  • 89Zr-Immuno-PET with Immune... 89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs
    Miedema, Iris H. C.; Wijngaarden, Jessica E.; Pouw, Johanna E. E. ... Cancers, 11/2023, Letnik: 15, Številka: 23
    Journal Article
    Recenzirano
    Odprti dostop

    Introduction: 89Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies (89ZrZr-mAbs)) can be used to study the biodistribution of mAbs targeting the immune ...
Celotno besedilo
Dostopno za: IZUM, KILJ, NUK, PILJ, PNG, SAZU, UL, UM, UPUK
9.
  • Impact of EDP-M on survival... Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study
    Debets, Pien; Dreijerink, Koen M A; Engelsman, Anton ... European journal of cancer 196
    Journal Article
    Recenzirano
    Odprti dostop

    Historically, stage IV adrenocortical carcinoma (mACC) has a poor prognosis with a median overall survival (OS) of only 5 months. Based on the FIRM-ACT trial published in 2012, guidelines now advise ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
10.
  • Immuno-Positron Emission To... Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
    Jauw, Yvonne W S; Menke-van der Houven van Oordt, C Willemien; Hoekstra, Otto S ... Frontiers in pharmacology, 05/2016, Letnik: 7
    Journal Article
    Recenzirano
    Odprti dostop

    Selection of the right drug for the right patient is a promising approach to increase clinical benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo biodistribution and ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
1 2 3 4 5
zadetkov: 83

Nalaganje filtrov